DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial

EuroIntervention 2016;12:e1336-e1342 published online ahead of print October 2015 published online e-edition December 2016. DOI: 10.4244/EIJY15M10_04

Javaid Iqbal
Javaid Iqbal1, MRCP, PhD; Stefan Verheye2, MD, PhD; Alexandre Abizaid3, MD, PhD; John Ormiston4, MB ChB; Ton de Vries5, MSc; Lynn Morrison6, MPH; Sara Toyloy6, BS; Peter Fitzgerald7, MD, PhD; Stephan Windecker8, MD, PhD; Patrick W. Serruys1,9*, MD, PhD; on behalf of EXCELLA II Investigators
1. Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands; 2. Academisch Ziekenhuis Middelheim, Antwerp, Belgium; 3. Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil; 4. Auckland City Hospital, Auckland, New Zealand; 5. Cardialysis BV, Rotterdam,

Aims: Newer-generation drug-eluting stents (DES) have been shown to be superior to first-generation DES. Current-generation DES have zotarolimus, everolimus or biolimus as antiproliferati

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

drug-eluting stentsnovolimuszotarolimus
Coronary interventionsStents and scaffoldsTools, devices and techniques
Read next article
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction

Latest news